Research
Hormonal
Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.
Choosing the right GLP-1 RA can significantly impact weight loss success.
StrongSupportsmedium confidence
Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.
Why this rating
Based on the analysis of weight loss outcomes related to medication type.
Source
Digital augmentation of glucagon-like peptide-1 (GLP-1) for obesity management: A retrospective study (Preprint)
Belinda Davey et al. · 2026
DOI 10.2196/preprints.100728
cohort · n=6753
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →